Results 21 to 30 of about 2,963,117 (406)
Materials & Design, 2023 Acute liver injury (ALI) is one of the most important causes of liver failure, and there are no FDA-approved drugs that could therapy late-stage ALI. It has been shown in this study that HA-PEI, a molecule formed by covalently combining HA and PEI, can ...
Mingqiao Li +10 more
doaj +1 more source
Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis
Nature Communications, 2023 The aetiology of primary biliary cholangitis (PBC) remains unclear. Here, the authors find that the numbers of DUOX2 + ACE2 + small cholangiocytes in human and mouse livers are inversely associated with disease severity, and present data indicating that ...
Xi Li +32 more
doaj +1 more source
Regulation of Lipid Metabolism by Lamin in Mutation-Related Diseases
Frontiers in Pharmacology, 2022 Nuclear lamins, known as type 5 intermediate fibers, are composed of lamin A, lamin C, lamin B1, and lamin B2, which are encoded by LMNA and LMNB genes, respectively.
Yue Peng +4 more
doaj +1 more source
Nonalcoholic Fatty Liver Disease [PDF]
Canadian Journal of Gastroenterology and Hepatology, 2018 According to the papers published in this special issue, NAFLD is a serious problem, which each author from their own aspect tried to clarify. Regarding the fact that NAFLD is rarely isolated and that it is correlated with obesity, diabetes type 2, polycystic ovarian syndrome, obstructive sleep apnea, and some cognitive deficits, its pathophysiology ...
Branka Filipović +3 more
openaire +5 more sources
International Journal of Molecular Sciences, 2023 To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment.
R. Nevola +8 more
semanticscholar +1 more source
MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.
Gastroenterology, 2020 Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. While pharmacotherapies are in development, response rates appear modest.
M. Eslam, A. Sanyal, J. George
semanticscholar +1 more source
BMC Endocrine Disorders, 2022 Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public health.
S. Pouwels +9 more
semanticscholar +1 more source
The effect of 12 weeks regular physical activity and vitamin E in the treatment of non-alcoholic steatohepatitis: A pilot study [PDF]
, 2015 Background: Despite the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), there was no treatment has been proven to be effective in these common diseases.
Eslami, L. +5 more
core +7 more sources
Global incidence and prevalence of nonalcoholic fatty liver disease
Clinical and Molecular Hepatology, 2022 Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide. The estimated global incidence of NAFLD is 47 cases per 1,000 population and is higher among males than females. The estimated global prevalence of NAFLD among adults
Margaret Teng +8 more
semanticscholar +1 more source
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome [PDF]
, 2016 There is evidence from animal and in-vitro studies that activation of the endocannabinoid system (EC) through cannabinoid receptor 1 (CB-1) is associated with liver injury, inflammation and hepatocellular carcinoma.1 Data suggests endogenous cannabinoids
Ahmed, Lina +6 more
core +1 more source